Tech Stock Trading Alert; Riverbed Technology (RVBD) Soars on Second Quarter Results

New York, NY - July 25, 2012 (InvestorIdeas.com Newswire) Investor Ideas, www.InvestorIdeas.com, a global investor research portal for independent investors, issues a tech stock trading alert for Riverbed Technology, Inc. (NasdaqGS :RVBD), trading up at $18.28 , gaining $ 3.73 or 25.64% as of 11:51AM EDT on over 13 Million shares. The Company reported Second Quarter results at the close yesterday.

GAAP revenue for Q2'12 was $198 million, an increase of 9% compared to $182 million in the first quarter 2012 (Q1'12) and an increase of 17% compared to $170 million in the second quarter 2011 (Q2'11). GAAP net income for Q2'12 was $18 million, or $0.11 per diluted share, compared to $7 million, or $0.04 per diluted share, in Q1'12 and $11 million, or $0.07 per diluted share, in Q2'11.
Non-GAAP revenue for Q2'12 was $199 million, an increase of 9% compared to $183 million in Q1'12 and an increase of 17% compared to $170 million in Q2'11. Non-GAAP net income for Q2'12 was $37 million, or $0.23 per diluted share, compared to $33 million, or $0.20 per diluted share, in Q1'12 and $35 million, or $0.21 per diluted share in Q2'11.
"We executed well in the second quarter, driving stronger sales of our new Steelhead and Cascade platforms, demonstrating continued demand for performance-improvement technologies," said Jerry M. Kennelly, Riverbed president and CEO. "Revenue grew across all major geographies and revenue growth accelerated across our core product offerings. Looking forward, we believe our expanded product offerings and partnerships will further extend our reach to new customers and market segments."
About Riverbed Technology
Riverbed delivers performance for the globally connected enterprise. With Riverbed, enterprises can successfully and intelligently implement strategic initiatives such as virtualization, consolidation, cloud computing, and disaster recovery without fear of compromising performance. By giving enterprises the platform they need to understand, optimize and consolidate their IT, Riverbed helps enterprises to build a fast, fluid and dynamic IT architecture that aligns with the business needs of the organization. www.riverbed.com
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Medical Technology Stock News Alert; PositiveID Corporation (OTCBB: PSID) Adds Chief Technology Advisor and Biodefense Expert as it Prepares for $3.1 Billion BioWatch Procurement

DELRAY BEACH, FL - July 25, 2012 - (Investorideas.com Newswire) PositiveID Corporation ("PositiveID" or “Company”) (OTCBB: PSID), an emerging growth company and developer of sophisticated airborne bio-threat detection systems for America’s homeland defense, today announced it has added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems (“MFS”) subsidiary. The Company will utilize Dr. Smith’s expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security (“DHS”) for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.

Dr. Smith has served as a Senior Advisor for International Biodefense for DHS’ Office of Health Affairs and was detailed to the U.S. State Department Office of International Health and Biodefense. Prior to this he served as the Acting Director of the National Biosurveillance Integration Center, where he set the vision and strategy of a U.S. government-wide effort to acquire, aggregate, integrate, analyze, interpret and disseminate all-source biosurveillance information from governmental and private sectors for epidemiological analyses and health protection.
Recently Dr. Smith was as a Senior Scientist for the Tahoe Research Initiative LLC, where he worked on global biosurveillance issues to build capacity and capability of public and veterinary health systems. Moreover, he was the Department of Homeland Security's first Chief Veterinarian and served as the Chief Scientist for the Office of Health Affairs. Prior to working with DHS, Dr. Smith worked at Lawrence Livermore National Laboratory LLNL, where he served as the Deputy Division Leader for Operations in the Counter-terrorism and Incident Response Division of the Non-proliferation, Arms Control and International Security Directorate. In this capacity Dr. Smith was responsible for maintenance and readiness of the laboratory’s nuclear response deployment and assessment teams. He earned his Ph.D. in molecular epidemiology from Louisiana State University (1999) where he curated the worldwide Bacillus anthracis collection.
William J. Caragol, Chairman and CEO of PositiveID, said, “We believe that Kimothy’s deep knowledge and experience in bioterrorism and biodefense strengthens our team as we move toward this important program.”
The Company’s M-BAND system was recently featured in a Bloomberg Businessweek article on the BioWatch procurement by DHS and can be read at:
http://www.businessweek.com/ articles/ 2012-06-21/ the-sky-high-price-of -sniffing-out-anthrax.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

TSX Tech Stock News; Q&A with TSX Technology Stock: SelectCore (TSX-V: SCG) Discusses Recent Contract with City of Toronto

New York, NY - July 24, 2012 (InvestorIdeas.com Newswire) Investor Ideas, www.InvestorIdeas.com, a global investor research portal for independent investors, issues a tech stock Q&A interview with Mr. Bryan Kenyon, Executive Vice President Financial Services, SelectCore Ltd. (TSX-V: SCG).

Mr. Kenyon discusses the Company's recent contract with the City of Toronto and what's next for one of Canada's fastest-growing companies.
Q: Investorideas.com staff
Mr. Kenyon, your Company just announced the details of a multi-year contract with the City of Toronto for the issuance of prepaid payment cards, with the first phase of the roll out for Toronto Employment and Social Services (TESS) for the delivery of Social Assistance disbursements. Can you give investors the significance of this contract in context of the services it provides?
A: Mr. Bryan Kenyon, Executive Vice President
This contract is a big step forward for social assistance recipients and the City of Toronto. The City Services Benefit Card is the first of its kind EMV (chip and PIN), instant-issue prepaid card program to be launched in North America. The introduction of the card replaces the need to produce paper cheques, resulting in significant cost savings for the City as well as for recipients who will no longer have to incur expensive cheque-cashing fees. This contract is very significant for SelectCore in the fact that having completed this highly complex implementation, we now have the technology, infrastructure, capabilities and expertise to deliver turn-key or completely customized check-replacement programs to any government agency in Canada.
Q: Investorideas.com staff
What is the potential revenue stream from this contract and over what period?
A: Mr. Bryan Kenyon, Executive Vice President
The potential high-margin revenue for the initial three-year period of the contract is estimated to be in the $15 million to $18 million dollar range.
Q: Investorideas.com staff
Do you see Federal Governments as potential clients and if so, what is the process for procuring contracts at that level?
A: Mr. Bryan Kenyon, Executive Vice President
We clearly see Federal Governments and the entire public sector as an emerging market for our prepaid payment solutions. Similar to the City of Toronto contract, we expect to competitively bid in various RFP processes initiated by not only federal, but also provincial and local government agencies. We intend to showcase our expertise and differentiated capabilities for delivering robust, cost effective and cardholder-friendly programs.
Q: Investorideas.com staff
Who is your competition in the marketplace and what are your competitive advantages?
A: Mr. Bryan Kenyon, Executive Vice President
Although the Canadian market for prepaid card programs is still in early growth stages, we do have a small number of companies that compete in our space. SelectCore however is well-positioned to compete in this market as we have a host of competitive advantages including first to market solutions and the experience necessary to help corporate clients and government agencies alike adopt prepaid card programs. Our platform is highly secure, reliable and has the flexibility to meet the demands of virtually any prepaid scenario. As a nimble organization, we are optimally suited to compete on price, service and product features and functionality.
About SelectCore
SelectCore Ltd. (TSX-V: SCG) is a pioneer and leader in prepaid payment solutions for underserved markets. Founded in 1999, the Company offers a range of prepaid products and services from stored-value cards to mobile top-up that provide financial empowerment to a market of millions of under-banked consumers. SelectCore has been ranked among Canada's fastest growing companies by Profit Magazine four times in the past six years and was included in the 2011 Deloitte Technology Fast 500 list of North America's fastest-growing technology companies. For more information visit www.selectcore.com .
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts including tech stocks and TSX stocks
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com

Biotech Investor News Alert: CFO of Sunshine Biopharma (OTCBB: SBFM) Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a

New York, New York - July 24, 2012 (Investorideas.com newswire, www.biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks issues follow-up commentary from Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) following recent news from the Company. Sunshine Biopharma reported it had engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.

Sunshine Biopharma's lead compound, Adva-27a, is a highly specific Topoisomerase II (Top2) Inhibitor and has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
Q: Investorideas.com staff
Camille, your Company announced on July 20 th that it had engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. To the novice investor, can you explain what the significance of this is towards the development of Adva-27a as an actual drug?
A: Mr. Camille Sebaaly, CFO
At the end of the month, Sunshine Biopharma will take delivery from Beta Pharma Canada two items:

• Adva-27a Compound
• Scale-up Manufacturing Protocol

The Adva-27a Compound part of the delivery is the actual Adva-27a drug which Beta Pharma Canada had synthesized and put through rigorous structure validation and chemical characterization processes including HPLC, Mass Spec and NMR (H, F, COSY, HMQC) analyses. Sunshine Biopharma will perform specific biological analyses on the material for confirmation of biological activity. These are standard procedures in initial drug manufacturing processes.
The Scale-up Manufacturing Protocol, which is the second part of the delivery from Beta Pharma Canada, will be vetted by Sunshine Biopharma then transferred to the large-scale (over 1 kilogram range) manufacturer for large-scale process development and manufacturing under GMP conditions. The material produced under GMP conditions will be used by Sunshine Biopharma to conduct IND-Enabling Studies and Phase I Clinical Trials in humans.
Read Investorideas.com First Q&A Interview with Mr. Camille Sebaaly, CFO
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
About Beta Pharma Canada
Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Wind Energy Stock News: Clean Wind Energy (OTCBB:CWET) Receives Efficient Energy Conversion Devices & Methods Patent

Annapolis, MD - July 23, 2012 (Investorideas.com renewable energy/green newswire) Clean Wind Energy Tower, Inc. (OTCBB:CWET) announced the publishing of its patent titled Efficient Energy Conversion Devices & Methods (U.S. Pat. No. 8,120,191) by the United States Patent and Trademark Office.

The patent covers specific aspects of deploying multiple turbines in a wind tunnel coupled to a novel hydraulic system capable of maintaining high efficiency hydraulic to electric conversion under a wide variance of wind speeds. The ultimate goal is to maximize the capture and utilization of all available wind energy in any given wind tunnel, as well as providing a consistency of power output during any deviations in wind speed. The Company considers this patent to be a "Core Patent" providing a significant barrier to entry for any potential competitor.
Ronald W. Pickett, President, Chief Executive Officer of CWET previously stated, "Our innovative solution of extracting the maximum energy generated by the captured wind, with the least loss of power throughout the transmission cycle from capture to exhaust, produces a much more consistent level of power output while compensating for the normal differentials in atmospheric conditions over any given period, and should coincide with our customers' requirements. The technological concepts and applications claimed and embodied within this patent provide significant benefits toward enhancing the level of efficient power generation, as well as reducing operational costs.
The annual capacity factor for the downdraft portion of the Energy Tower is predicted at approximately 51%.  Prime production periods are daytime and evening during spring, summer and fall, which closely align with electricity demand patterns. However, the External Wind Capture keeps working 24/7, whenever a wind is blowing, including cold winter months and at night.  Its capacity factor is estimated at approximately 75%, which raises the Energy Tower's overall capacity factor to above 60%. Clean Wind believes that the Downdraft Tower will be capable of recapturing and recycling the vast majority of the water used to create the downdraft. This water may be returned to be reused in the Downdraft Tower or diverted for local potable water.
As currently designed, the Company anticipates that each Downdraft Tower will be capable of generating up to 1,200 megawatts per hour of salable electricity to the grid. One megawatt equates to 1,000,000 watts or 1,000 kilowatts of electricity. Currently, avoided costs per kilowatt in California are running approximately $0.11 per kilowatt hour.
About Clean Wind Energy, Inc.
Clean Wind Energy, Inc. a wholly owned subsidiary of Clean Wind Energy Tower, Inc, has designed and is preparing to develop, and construct large "Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies.
Our Company's core objective and focus is to become a leading provider of clean efficient green energy to the world communities at a reasonable cost without the destructive residuals of fossil fuel, while continuing to generate innovative technological solutions for today and tomorrow's electrical power needs.
In addition to constructing Downdraft Towers in the United States and abroad, the Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity. Clean Wind has assembled a team of experienced business professionals, engineering and scientific consultants with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market.
Clean Wind has filed several patents that the Company believes will further enhance this potentially revolutionary technology. Clean Wind Energy, Inc. is based in Annapolis MD, and is traded on the OTCBB under the symbol ‘CWET' . For more information, please visit www.cleanwindenergytower.com.
Contact:
Clean Wind Energy, Inc.
1997 Annapolis Exchange Parkway Suite 300
Annapolis, Maryland 21401
Phone: 410-972-4713
E-mail: Info@cwetower.com
www.cleanwindenergytower.com
Investor Relations Contact:
Jody Janson
Phone: (855) 848-6937
Email: ir@cwetower.com
Cautionary Note Regarding Forward-Looking Statements
Statements included in this release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company's financial results, can be found in the Company's various filings with the Securities and Exchange Commission (SEC).

Visit the CWET showcase page at Investorideas.com:
http://www.investorideas.com/CO/CWE/

Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp

About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.

Sign up at Investor Ideas for free investor alerts including news on wind stocks
http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) publishing program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand per month to publish news and updates on the company on Investorideas.com newswire and blogs . Investorideas.com owns 150,000 shares of 144 stock .Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com

Homeland Defense and Security Q&A Interview with PositiveID (OTCBB: PSID): How the M-BAND System Biothreat Detection is in the Running for BioWatch

New York, NY - July 23, 2012 - (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveID Corporation (OTCBB: PSID) discussing its M-BAND System for biothreat detection.

Q: Investorideas.com
Can you briefly explain to new investors how the M-BAND System works and how it can be deployed in the BioWatch Generation 3 program?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Our Microfluidics-based Bioagent Networked Detector, called M-BAND, was developed under contract for the Department of Homeland Security (DHS), and is an early warning system designed to detect the intentional release of aerosolized biological agents. It runs autonomously for up to 30 days between service cycles, continuously analyzing air samples, typically in high-traffic areas, for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for instruments in the field in aggregate. M-BAND was designed with a high level of operational flexibility, and can be remotely set to detect for DNA-based pathogens alone, with or without either RNA-based organisms or toxins, or for all three types of pathogens simultaneously at remotely programmable intervals.
Q: Investorideas.com
We understand the Department of Homeland Security wants to open bidding before October for Generation 3 of the BioWatch program, now estimated at $5.7 Billion. Where is PSID in the process?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We are currently awaiting the final RFP from the Department of Homeland Security, which is expected to be released later this year. In the meantime, we have made significant progress in our internal testing of M-BAND, which detects five organisms on the Centers for Disease Control Select Agents List, which is a requirement for BioWatch. Our system is fully functional and, we believe, one of the only technologies capable of addressing the requirements of the BioWatch procurement. We are preparing for potential additional testing of our system as well.
Q: Investorideas.com
The other company bidding for the BioWatch program is Northrop Grumman (NYSE:NOC); is this competitive against your technology or more synergistic?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We believe the M-BAND instrument offers a number of advantages over similar products, including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation. M-BAND has been designed and field tested (both indoors and outdoors) to operate continuously for 30 days unattended between scheduled services, which we believe to be higher than competing technologies. It also operates using industry gold-standard TaqMan® PCR (polymerase chain reaction) chemistry.
Q: Investorideas.com
Your Company was recently featured in a Bloomberg Businessweek.com article discussing BioWatch; did that lend a new level of credibility for your company being a small OTC listed stock?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We believe articles like the one published in Bloomberg Businessweek shed light on the need for BioWatch Generation 3, and also highlight and validate our technology and our company. Many people may not have been previously aware of PositiveID or M-BAND, so it was very significant for our company and technology to be featured alongside the likes of Northrop Grumman. We have already received additional inquiries and interest from large corporations around the world including for possible partnership opportunities, as well as increased investor interest.
Q: Investorideas.com
Are you targeting any other markets forthe M-BAND System globally?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Unfortunately, terrorism is not limited to the United States, so M-BAND could be deployed in any location around the globe. In fact, the system has been field tested in London.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Nanotechnology Energy Stocks News; mPhase Technologies, Inc. (OTC.BB:XDSL) Invited for Second Visit to French Technology Cluster

LITTLE FALLS, NJ - July 20, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) reported today that it is completing arrangements for a second visit during September of 2012, by invitation, from certain agencies of the French government, of the Grenoble Technology Cluster known as Minalogic (http://www.minalogic.org). The Cluster consists of government, corporate and educational members that are engaged in high technology research in the leading scientific disciplines such as micro- and nano-technologies and embedded systems on chips.

A global competitive Cluster Minalogic fosters research-led innovation in intelligent miniaturized products and solutions for industry. Located in Grenoble, France, the Cluster channels in a single physical location range of highly-specialized skills and resources from knowledge creation to the development and production of intelligent miniaturized services for industry.
Minalogic has staked out a position as global leader in intelligent miniaturized solutions -- a unique hybrid of micro- and nano-technologies and embedded software -- from fundamental research to technology transfer.
The technologies developed at the Cluster are applicable to all business sectors, including more traditional industries. The role of Minalogic is to respond to the business community's need to identify new value-added services that can be integrated into existing products in fields that include health care, the environment, mobility, the media, and the textile industry.
Minalogic brings together major corporations, small and mid-sized businesses, government agencies, and organizations from the public and private sectors. The Cluster's focus on innovation and its participatory governance model are designed with one objective in mind: to ensure efficient, results-oriented cooperation among Cluster partners.
The Company first visited the Cluster in March of 2012 after the relevant agencies reviewed mPhase's patent portfolio and the recent valuation and product applications that could result from potential licenses of various patents contained in the portfolio. The purpose of the second visit is to continue discussions with potential large strategic partners seeking to use the Company's Smart NanoBattery as a component in a new or established end product. It is anticipated that upon the establishment of such a strategic partnership continued research to custom tailor the Smart NanoBattery would continue at one of the Cluster's laboratory facilities at Grenoble, France. All potential strategic partners are currently members of the Cluster.
The scientific focus and interest is based upon the ability of mPhase's Smart Surface technology to electronically control the precise flow of a fluid on a nano-structured surface.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website: http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.

Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.

Small Cap Biotech Stock News: SUNSHINE BIOPHARMA (OTCBB: SBFM) Begins MANUFACTURING OF Adva-27a Anti Cancer Compound

Montreal, Quebec, Canada - July 20, 2012 (Investorideas.com newswire) - Small Cap Biotech stock news alert: Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports it has engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.

Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai (China).
Beta Pharma Canada Inc., headquartered in Montreal (Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds.
Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
"We are delighted to be working with Beta Pharma Canada with excellent in-house synthesis capability and can amass additional resources through its corporate affiliations", said Dr. Steve N. Slilaty, Sunshine's President and CEO. "We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month", he added.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at Investorideas.com Newswire
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 www.Investorideas.com

Published at Investorideas.com newswire

Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Homeland Defense Stock Alert: IDO Security (OTC: IDOI) Moves over 27%

New York, NY - July 19, 2012 (Investorideas.com Newswire, www.Homelanddefensestocks.com) www.InvestorIdeas.com, a global investor research portal, specializing in sector research for independent investors, issues a trading alert for Homeland Defense stock, IDO Security Inc. (OTC:IDOI), the developer of theMagShoe™ shoe scanning device (SSD). The stock is trading up at $0.47, gaining 0.10(27.03%) on over 1.8 Million shares.
The average trading volume for the stock is 102,000. There was no news issued from the Company today, but the stock was featured in several microcap newsletters.
About IDO Security, Inc.
Headquartered in New York with a subsidiary in Israel, IDO Security designs, develops and markets the patented MagShoe™ shoe scanning device (SSD), filling a critical void in today's detectors by extending screening to the lower body and feet. MagShoe™'s "shoes-on" design maximizes security, thoroughness and accuracy while eliminating the need to remove shoes for increased convenience and safety; neither invasive nor harmful to the body as some of the other screening devices currently used in the marketplace. Ideal for security and loss prevention at virtually any facility, MagShoe™ is currently in use worldwide at international airports, cruise lines, government agencies, correctional facilities, mints and more.

http://www.idosecurityinc.com
Research defense and security stocks with the Investorideas.com defense and security stocks Directory:
http://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Investorideas.com and its defense portal www.Homelanddefensestocks.comwasone of the first sites to cover Homeland Defense stocks and was quoted as a source in Businessweek.com and CNN Financial News on the sector.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com on Google Plus https://plus.google.com/116622008917768549777
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . I nvestorideas.com was not compensated for this report
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Biotech Stock Trading Alert: Sunshine Biopharma (OTCBB: SBFM) Trades up over 10% on News of Manufacturing Adva-27a

New York, New York –July 19, 2012 –(Investorideas.com Newswire,Biotechindustrystocks.com)     Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM). The stock is trading
up over 10% on news of manufacturing Adva-27a.

The Company reported that it has engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).



Recent Q&A with Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) at Investorideas.com
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp

About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com


About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

 Sign up for the free investor news and biotech stock alerts

Research biotech stocks at the Investor Ideas Biotech stocks Directory

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source – www.Investorideas.com

Biotech Stock Alert: SUNSHINE BIOPHARMA (OTCBB:SBFM) ENGAGES BETA PHARMA CANADA FOR MANUFACTURING OF AN INITIAL BATCH OF Adva-27a

Montreal, Quebec, Canada - July 19, 2012 (Investorideas.com newswire) - Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).

"We are delighted to be working with Beta Pharma Canada with excellent in-house synthesis capability and can amass additional resources through its corporate affiliations", said Dr. Steve N. Slilaty, Sunshine’s President and CEO. "We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month", he added.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at Investorideas.com Newswire
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 www.Investorideas.com

Published at Investorideas.com newswire

Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894